Open an account

Vivos Therapeutics

VVOS · NASDAQ

$0.1406+$0.0057 (+4.23%)TodayMarket closed ·
Prev close $0.1349

VVOS analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy2
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 5 analysts

Average $2.16 (+1435.6% upside)

Low
$0.7575
Now
$0.1406
High
$3.26

Upgrades and downgrades

The latest rating actions, newest first

VVOS analyst upgrades, downgrades and rating actions
FirmDateActionRating
Ascendiant CapitalJun 4, 2026MaintainsBuy
Ascendiant CapitalApr 22, 2026MaintainsBuy
HC Wainwright & Co.Apr 17, 2026MaintainsBuy
Ascendiant CapitalDec 3, 2025MaintainsBuy
HC Wainwright & Co.Nov 17, 2025InitiatesBuy

The case for and against

Updated Oct 7, 2026

Bull case

Vivos Therapeutics is attractive because its non-surgical, non-pharmaceutical OSA platform addresses a large unmet need with better compliance potential than CPAP, while the company’s position in a market affecting over 30 million U.S. adults supports meaningful long-term expansion. Operationally, revenue grew 16.0% in 2025 to $17.4 million, and gross margin improved sharply to 78% in Q4 from 58% in Q3, suggesting improving economics as the channel expands through sleep centers and partnerships. Despite a 2025 net loss of $21.2 million and execution risks from provider attrition and capital needs, the combination of higher margins, cost controls, and accretive acquisition opportunities supports a constructive outlook.

Bear case

Vivos Therapeutics is facing a difficult transition as Q4 FY25 revenue fell to $3.8 million versus a $7.3 million estimate, with the decline tied to weaker product sales while shifting from the legacy VIP/dentist model to the sleep-center model. The new strategy is proving operationally slow and costly, since management cited prescriber hiring constraints, operating expenses rose 90% year over year to $9.4 million, and net loss widened to $7 million. Liquidity remains strained, with $2.0 million of cash at the end of December 2025, $8.8 million of debt, $15.3 million of operating cash burn during 2025, and share count increasing to 13.5 million after roughly $6.8 million of subsequent financings, signaling continued dilution and financing risk.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.